Brainsway Ltd. (BWAY) – Press Releases
-
BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024
-
BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates
-
BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease
-
BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis
-
BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems
-
BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights
-
BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
-
BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology
-
BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network
-
BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea
-
Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives
-
BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights
-
Clinical TMS Society Publishes First Coverage Recommendations for the Treatment of Smoking Addiction
-
BrainsWay to Report Third Quarter 2023 Financial Results on November 15, 2023
-
BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Depression
-
BrainsWay Announces Presentation of Two Deep TMS™ Posters at Upcoming World Congress of Psychiatry
-
BrainsWay Broadens Access to Deep TMS™ for U.S. Military Service Members Through Expanded Partnership with Katie’s Way Plus
-
BrainsWay Forges Strategic Partnership with Treatment Provider in Northeast U.S.
-
BrainsWay Further Expands Access to Deep TMS™ in Asia Pacific Region
-
BrainsWay Reports Second Quarter 2023 Financial Results and Operational Highlights
-
BrainsWay Announces Publication of Three New Deep TMS Research Publications
-
BrainsWay Accelerates International Expansion in India
-
BrainsWay Announces Significant Expansion in Western and Central U.S.
-
BrainsWay Announces Appointment of Ido Marom as CFO
-
BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights
-
BrainsWay Launches Investigator Initiated Study (IIS) Program
-
BrainsWay to Participate in Clinical TMS Society and American Psychiatric Association Meetings
-
BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression
-
BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights
-
BrainsWay Named to Fast Company’s 2023 List of the World’s Most Innovative Companies
-
BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023
-
BrainsWay Vice President of Medical Affairs Colleen Hanlon Honored with the 2023 International Brain Stimulation Early Career Award
-
BrainsWay Announces Appointment of Ami Boehm as New Chairman
-
BrainsWay Announces Appointment of Hadar Levy as CEO
-
BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™
-
BrainsWay Resolves Neuronetics Litigation
-
BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom
-
BrainsWay Reports Open Market Stock Purchases by Two Board Members
-
BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights
-
BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™
-
BrainsWay to Report Third Quarter Financial Results on November 16, 2022
-
BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs
-
BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month
-
BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments
-
BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley
-
BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™
-
BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference
-
BrainsWay Receives New FDA Clearance for Treating Depression and Anxious Depression
-
BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights
-
BrainsWay to Report Second Quarter Financial Results on August 10, 2022
Back to BWAY Stock Lookup
